Evaluation of the effectiveness of the reconsolidation therapy in a clinical population suffering from post-traumatic stress disorder

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500870-32-02

Acronym

ULB-PTSD-Propranolol

Enrollment

Registered

2023-02-28

Start date

2023-10-04

Completion date

Unknown

Last updated

2023-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-traumatic stress disorder

Brief summary

PCL-S: Posttraumatic stress disorder Checklist Scale.

Detailed description

PANAS: Positive And Negative Affect Schedule., HADs: Hospital Anxiety and Depression scale., DERS: Difficulties in Emotion Regulation Scale., HRV: Heart Rate Variability by a clock Polar V800.

Interventions

DRUGInderal 10 mg film-coated tablets.

DRUGInderal 40 mg film-coated tablets.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PCL-S: Posttraumatic stress disorder Checklist Scale.	—

Secondary

Measure	Time frame
PANAS: Positive And Negative Affect Schedule., HADs: Hospital Anxiety and Depression scale., DERS: Difficulties in Emotion Regulation Scale., HRV: Heart Rate Variability by a clock Polar V800.	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026